(NASDAQ: ATHA) Athira Pharma's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 17.83%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 23.31%.
Athira Pharma's earnings in 2025 is -$96,940,000.On average, 1 Wall Street analyst forecast ATHA's earnings for 2025 to be -$32,014,805, with the lowest ATHA earnings forecast at -$32,014,805, and the highest ATHA earnings forecast at -$32,014,805. On average, 1 Wall Street analyst forecast ATHA's earnings for 2026 to be -$31,624,380, with the lowest ATHA earnings forecast at -$31,624,380, and the highest ATHA earnings forecast at -$31,624,380.
In 2027, ATHA is forecast to generate -$30,062,683 in earnings, with the lowest earnings forecast at -$30,062,683 and the highest earnings forecast at -$30,062,683.